Document Detail


Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
MedLine Citation:
PMID:  17327954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the effect of valproic acid on plasma levels of risperidone and its active metabolite, 9-hydroxyrisperidone under steady state conditions in 12 schizophrenic patients. METHODS: The efficacy and tolerability for the combination treatment of valproic acid and risperidone were examined. RESULTS: The addition of valproic acid to risperidone significantly reduced total scores of PANSS positive symptoms, especially excitement and hostility scores, but did not change SAS scores. Addition of valproic acid did not alter plasma concentrations of risperidone or 9-hydroxyrisperidone or active moiety, and the risperidone/9-hydroxyrisperidone ratio. The combination of valproic acid with risperidone decreased plasma levels of HVA, but not those of MHPG; additionally, treatment with this combination was found to reduce dopaminergic activity. CONCLUSION: These results suggest that the addition of valproic acid to risperidone is both effective and well tolerated for treating excitement and impulsiveness in schizophrenic patients without influencing the metabolism of risperidone, and treatment with valproic acid and risperidone.
Authors:
R Yoshimura; K Shinkai; N Ueda; J Nakamura
Related Documents :
18564764 - Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmo...
8745384 - Valproic acid treatment of learning disorder and severely epileptiform eeg without clin...
23728324 - Physico-chemical characterisation of the fat from red-skin rambutan (nephellium lappace...
9591934 - Detection of a drug-drug interaction on population-based phenobarbitone clearance using...
14980424 - Elastin stabilization in cardiovascular implants: improved resistance to enzymatic degr...
6813884 - Effect of sulfinpyrazone on the metabolism of arachidonic acid in isolated hamster lungs.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacopsychiatry     Volume:  40     ISSN:  0176-3679     ISO Abbreviation:  Pharmacopsychiatry     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-28     Completed Date:  2007-04-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8402938     Medline TA:  Pharmacopsychiatry     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  9-13     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku Kitakyushu, Fukuoka 8078555, Japan. yoshi621@med.uoeh-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antimanic Agents / adverse effects,  therapeutic use*
Antipsychotic Agents / adverse effects,  blood*,  therapeutic use
Drug Interactions
Female
Homovanillic Acid / blood
Humans
Isoxazoles / blood
Male
Methoxyhydroxyphenylglycol / blood
Middle Aged
Psychiatric Status Rating Scales
Psychomotor Agitation / complications,  drug therapy*
Pyrimidines / blood
Risperidone / adverse effects,  blood*,  therapeutic use
Schizophrenia / complications*,  drug therapy
Schizophrenic Psychology
Valproic Acid / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antimanic Agents; 0/Antipsychotic Agents; 0/Isoxazoles; 0/Pyrimidines; 106266-06-2/Risperidone; 144598-75-4/9-hydroxy-risperidone; 306-08-1/Homovanillic Acid; 534-82-7/Methoxyhydroxyphenylglycol; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
Next Document:  Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors.